Research programme: RNA therapeutics - Arcturus Therapeutics/Janssen Pharmaceuticals

Drug Profile

Research programme: RNA therapeutics - Arcturus Therapeutics/Janssen Pharmaceuticals

Alternative Names: Human alpha-1 antitrypsin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human cystic fibrosis transmembrane conductance messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human erythropoietin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human factor IX messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; Human tumor protein p53 messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-101; LUNAR-102; LUNAR-CF; LUNAR-FIX; LUNAR-hepcidin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-HPN; LUNAR-ornithine transcarbamylase messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-OTC; LUNAR-thrombopoietin messenger RNA - Arcturus Therapeutics/Janssen Pharmaceuticals; LUNAR-TPO; mRNA CFTR therapeutic - Arcturus Therapeutics

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcturus Therapeutics
  • Class Antianaemics; Antifibrotics; Antineoplastics; MicroRNAs; RNA; Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Amyloid polyneuropathy; Amyloidosis; Anaemia; Cystic fibrosis; Haemophilia B; Inborn urea cycle disorders
  • Research Cancer; Iron overload; Thrombocytopenia

Most Recent Events

  • 30 May 2017 Arcturus Therapeutics and Cystic Fibrosis Foundation Therapeutics for the development of LUNAR-CF for Cystic fibrosis
  • 30 May 2017 Arcturus Therapeutics has patent protection for LUNAR™ nanoparticle delivery and UNA technology in USA, Europe, Japan, China and other countries before May 2017
  • 16 Mar 2016 Arcturus Therapeutics receives intent to grant notice from the European Patent Office for their unlocked nucleomonomer agent (UNA) Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top